Postmortem distribution of mitragynine and 7-hydroxymitragynine in 51 cases.

J Anal Toxicol

Tarrant County Medical Examiner's Office, Fort Worth, TX 76104, United States.

Published: February 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The prevalence of mitragynine (kratom) in forensic toxicology casework has steadily increased over time. Readily available and currently legal, mitragynine is widely used for its stimulant and, depending on concentration, sedative effects. Our laboratory analyzed various fluid and tissue specimens from 51 postmortem cases to investigate the distribution of mitragynine and its active metabolite 7-hydroxymitragynine. Central and peripheral blood concentrations were compared, with an average heart blood to femoral blood ratio being 1.37 for mitragynine and 1.08 for 7-hydroxymitragynine. This ratio >1.0 suggests that mitragynine has some propensity toward postmortem redistribution; however, the difference in concentrations of mitragynine and 7-hydroxymitragynine is not statistically significant. Large average mitragynine to 7-hydroxymitragynine ratios of 30.9 in femoral blood and 32.4 in heart blood were observed compared to average ratios of 14.8 in vitreous humor and 16.9 in urine. In addition, the stability of these two compounds was investigated in both matrix and organic solvent. When stored refrigerated (4°C), mitragynine was stable for up to 30 days and 7-hydroxymitragynine was stable for up to 7 days with an analyte loss of <20%. Following 60 days of refrigerated storage, 7-hydroxymitragynine concentrations dropped over 50% from initial concentrations. Methanolic preparations of mitragynine and 7-hydroxymitragynine were stable following 3 months of storage at -20°C.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jat/bkae099DOI Listing

Publication Analysis

Top Keywords

mitragynine 7-hydroxymitragynine
12
mitragynine
9
distribution mitragynine
8
compared average
8
heart blood
8
femoral blood
8
7-hydroxymitragynine
6
blood
5
postmortem distribution
4
7-hydroxymitragynine cases
4

Similar Publications

The Impact of Diverse Kratom Products on Use Patterns, Dependence, and Toxicity.

Curr Psychiatry Rep

August 2025

University of Florida College of Pharmacy, 1345 Center Drive, Room P3-12, Gainesville, FL, 32611, USA.

Purpose Of Review: Kratom products have been available in the US for over a decade. Initially, these products were almost entirely made from kratom leaf material and formulated in powders, capsules, or tablets. Recently, more diverse kratom products and derivatives have been marketed and sold, including extracts, concentrates, and isolates.

View Article and Find Full Text PDF

Objectives: There is an increased interest in kratom and kratom-related products such as 7-hydroxymitragynine (7-OH). Here we present the case of a patient seeking inpatient substance use treatment for daily 7-OH use and the clinical course of care including clinical opiate withdrawal scale (COWS) and medication treatment response.

Methods: This is a single case report from an inpatient medically managed withdrawal level of substance use treatment care.

View Article and Find Full Text PDF

Screening, docking, and molecular dynamics analysis of Mitragyna speciosa (Korth.) compounds for targeting HER2 in breast cancer.

Curr Res Struct Biol

December 2025

Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Lambung Mangkurat, Jl. Brig Jend. Hasan Basri, Banjarmasin, South Kalimantan, 70123, Indonesia.

Breast cancer remains the most commonly diagnosed cancer among women worldwide, with approximately 2.3 million new cases reported in 2022. In the United States alone, an estimated 310,720 new cases of female breast cancer are expected in 2024.

View Article and Find Full Text PDF